Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Summary:

  • On 06/11/24, I published an article on Affimed focused on my belief the company’s upcoming acimtamig update would be positive. It was, and Affimed’s stock popped the next day.
  • The stock has since dropped to below $4/s based, in my opinion, on investor’s perceptions that a dilutive capital raise is coming soon.
  • AFMD’s 2Q ’24 Earnings Call is scheduled for tomorrow, 09/05/24. And we are due for an acimtamig and AFM24 3Q ’24 update before the end of the month.
  • Abstracts for ESMO’24 are posted on 09/06/24 and the WCLC starts 09/07/24…will we get the AFM24 update before acimtamig’s?
  • While AFMD’s assets have shown promise, a potential investment carries high risk and may not be suitable for most investors.

Natural killer cells attacking a cancer cell

selvanegra

Introduction

I am going to touch on key highlights from my article on Affimed NV (NASDAQ:AFMD) on 06/11/24 and additional updates from the company given a day later in their 1Q ’24 Financial Results & Business Update


Analyst’s Disclosure: I/we have a beneficial long position in the shares of AFMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *